Leukocyte telomere length (LTL) shortens with age and may be related to multiple sclerosis (MS).
Objective:
We hypothesize that chronologically young people with MS (pwMS) with short LTL behave similarly to older MS subjects.
Methods:
Prospective 2-year study including two cohorts of young (18–35 years) and elderly (⩾50 years) pwMS with similar disease duration. Physical and cognitive evaluation, 3 T brain magnetic resonance imaging (MRI) and retinal nerve fiber layer (RNFL) measurement by optical coherence tomography were performed. LTL was measured by quantitative polymerase chain reaction assay.
Results:
Around 105 patients were included, 57 young and 48 elderly. LTL was shorter in older patients (0.61 versus 0.57, p = 0.0081) and in males (female, 0.60; male, 0.59; p = 0.01335). For every 10-year increase in age, LTL was 0.02 U shorter. In elderly, LTL correlated with disease duration (p = 0.05), smoking (p = 0.03), Expanded Disability Status Scale (EDSS; p = 0.004), 9HPT (p = 0.00007), high-efficacy therapies (p = 0.001), brain lesion volume (BLV) (p = 0.011), and number of T2 lesions (p = 0.01). In young patients, LTL did not correlate with clinical or radiological variables. For every 0.1 U shorter LTL, gray matter volume decreased 1.75 cm3 and white matter volume 1.78 cm3.
Conclusion:
LTL correlated with disability and BLV in elderly. Besides LTL shortening, other variables should be considered as mechanisms of neurodegeneration that might be involved in aging pwMS.
ReichDSLucchinettiCFCalabresiPA. Multiple sclerosis. N Engl J Med2018; 378: 169–180.
2.
HittleMCulpepperWJLanger-GouldA, et al. Population-based estimates for the prevalence of multiple sclerosis in the United States by race, ethnicity, age, sex, and geographic region. JAMA Neurol2023; 80: 693–701.
3.
ChakravartiDLaBellaKADePinhoRA. Telomeres: History, health, and hallmarks of aging. Cell2021; 184: 306–322.
AstutiYWardhanaAWatkinsJ, et al. Cigarette smoking and telomere length: A systematic review of 84 studies and meta-analysis. Environ Res2017; 158: 480–489.
6.
TopiwalaATaschlerBEbmeierKP, et al. Alcohol consumption and telomere length: Mendelian randomization clarifies alcohol’s effects. Mol Psychiatry2022; 27: 4001.
7.
BellonMNicotC. Telomere dynamics in immune senescence and exhaustion triggered by chronic viral infection. Viruses2017; 9: 289.
8.
ChenSYehFLinJ, et al. Short leukocyte telomere length is associated with obesity in American Indians: The strong heart family study. Aging2014; 6(5): 380–389.
9.
DuMPrescottJKraftP, et al. Physical activity, sedentary behavior, and leukocyte telomere length in Women. Am J Epidemiol2012; 175: 414.
10.
FesslerJAngiariS. The role of T cell senescence in neurological diseases and its regulation by cellular metabolism. Front Immunol2021; 12: 706434.
11.
LiuMLuoPLiuL, et al. Immune-mediated inflammatory diseases and leukocyte telomere length: A Mendelian randomization study. Front Genet2023; 14: 1129247.
12.
MinerAEGravesJS. What telomeres teach us about MS. Mult Scler Relat Disord2021; 54: 103084.
13.
KryskoKMHenryRGCreeBAC, et al. Telomere length is associated with disability progression in Multiple Sclerosis. Ann Neurol2019; 86(5): 671–682.
14.
HabibROcklenburgSHoffjanS, et al. Association between shorter leukocyte telomeres and multiple sclerosis. J Neuroimmunol2020; 341: 577187.
15.
GuanJZGuanWPMaedaT, et al. Patients with multiple sclerosis show increased oxidative stress markers and somatic telomere length shortening. Mol Cell Biochem2015; 400(1-2): 183–187.
16.
HeckerMFitznerBJägerK, et al. Leukocyte telomere length in patients with multiple sclerosis and its association with clinical phenotypes. Mol Neurobiol2021; 58(6): 2886–2896.
17.
ThompsonAJBanwellBLBarkhofF, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol2018; 17: 162–173.
18.
KurtzkeJF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology1983; 33: 1444–1452.
19.
FeysPLamersIFrancisG, et al. The Nine-Hole Peg test as a manual dexterity performance measure for multiple sclerosis. Mult Scler2017; 23(5): 711–720.
20.
MotlRWCohenJABenedictR, et al. Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis. Mult Scler2017; 23(5): 704–710.
21.
LublinFDHäringDAGanjgahiH, et al. How patients with multiple sclerosis acquire disability. Brain2022; 145: 3147–3161.
22.
RaoSMLeoGJBernardinL, et al. Cognitive dysfunction in multiple sclerosis. I. Frequency, Patterns, and Prediction. Neurology1991; 41: 685–691.
23.
SerranoCMSorbaraMMinondA, et al. Validation of the Argentine version of the montreal cognitive assessment test (MOCA) a screening tool for mild cognitive impairment and mild dementia in elderly. Dement Neuropsychol2020; 14(2): 145–152.
24.
BuschkeH. Selective Reminding for analysis of memory and learning. J Verbal Learning Verbal Behav1973; 12: 543–550.
25.
BarbizetJCanyE. Clinical and psychometrical study of a patient with memory disturbances. Int J Neurol1968; 7(1): 44–54.
26.
ButtersNGranholmESalmonDP, et al. Episodic and semantic memory: A comparison of amnesic and demented patients. J Clin Exp Neuropsychol1987; 9(5): 479–497.
27.
BollaKILindgrenKNBonaccorsyC, et al. Predictors of verbal fluency (FAS) in the healthy elderly. J Clin Psychol1990; 46(5): 623–628.
28.
GronwallDMA. Paced auditory serial-addition task: A measure of recovery from concussion. Percept Mot Skills1977; 44: 367–373.
29.
StroberLDeLucaJBenedictRH, et al. Symbol digit modalities test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis. Mult Scler2019; 25(13): 1781–1790.
30.
ZigmondASSnaithRP. The hospital anxiety and depression scale. Acta Psychiatr Scand1983; 67: 361–370.
31.
KruppLBLaRoccaNGMuir-NashJ, et al. The fatigue severity scale: Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol1989; 46(10): 1121–1123.
GoodyearMDEKrleza-JericKLemmensT. The declaration of Helsinki. Br Med J2007; 335: 624–625.
34.
ScalfariANeuhausADaumerM, et al. Age and disability accumulation in multiple sclerosis. Neurology2011; 77: 1246–1252.
35.
ScalfariA. MS progression is predominantly driven by age—related mechanisms—YES. Mult Scler2019; 25: 902–904.
36.
TutuncuMTangJZeidNA, et al. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler2013; 19(2): 188–198.
37.
FulopTLarbiAPawelecG, et al. Immunology of aging: The birth of inflammaging. Clin Rev Allergy Immunol2023; 64: 109–122.
38.
FranceschiCBonafèMValensinS, et al. Inflamm-aging: An evolutionary perspective on immunosenescence. Ann N Y Acad Sci2000; 908: 244–254.
39.
PerdaensOvan PeschV. Molecular mechanisms of immunosenescene and inflammaging: Relevance to the immunopathogenesis and treatment of multiple sclerosis. Front Neurol2021; 12: 811518.
40.
EitanEHutchisonERMattsonMP. Telomere shortening in neurological disorders: An abundance of unanswered questions. Trends Neurosci2014; 37(5): 256–263.
41.
O'DonovanAPantellMSPutermanE, et al. Cumulative inflammatory load is associated with short leukocyte telomere length in the health, aging and body composition study. PLoS ONE2011; 6(5): e19687.
42.
JaiswalMLaRussoNBurgartL, et al. Inflammatory cytokines induce DNA damage and Inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent Mechanism1. Cancer Res2000; 60: 184–190.
43.
GardnerMBannDWileyL, et al. Gender and telomere length: Systematic review and meta-analysis. Exp Gerontol2014; 51: 15–27.
44.
AvivA. Telomeres, sex, reactive oxygen species, and human cardiovascular aging. J Mol Med2002; 80(11): 689–695.
45.
AzevedoCJCenSYKhadkaS, et al. Thalamic atrophy in multiple sclerosis: A magnetic resonance imaging marker of neurodegeneration throughout disease. Ann Neurol2018; 83(2): 223–234.
46.
CiampiEUribe-San-MartinRSolerB, et al. Prevalence of comorbidities in Multiple Sclerosis and impact on physical disability according to disease phenotypes. Mult Scler Relat Disord2020; 46: 102565.
47.
YsrraelitMCCorrealeJ. Impact of sex hormones on immune function and multiple sclerosis development. Immunology2019; 156(1): 9–22.
48.
ZárateSStevnsnerTGredillaR. Role of estrogen and other sex hormones in brain aging. Front Aging Neurosci2017; 9: 430.
49.
DabrowskaAVeneroJIwasawaR, et al. PGC-1α controls mitochondrial biogenesis and dynamics in lead-induced neurotoxicity. Aging2015; 7: 629–647.
50.
GomesAPriceNLingAJY, et al. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell2013; 155: 1624–1638.
51.
MariottiniAMuraroPALünemannJD. Antibody-mediated cell depletion therapies in multiple sclerosis. Front Immunol2022; 13: 953649.
52.
KaszubowskaL. Telomere shortening and ageing of the immune system. J Physiol Pharmacol2009; 59(Suppl. 9): 169–186
53.
JoseSSBendickovaKKepakT, et al. Chronic inflammation in immune aging: Role of pattern recognition receptor crosstalk with the telomere complex. Front Immunol2017; 8: 1078.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
